ASLAN 003

Drug Profile

ASLAN 003

Alternative Names: ASLAN003; LAS 186323

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Laboratorios Almirall
  • Developer Almirall S.A.; ASLAN Pharmaceuticals
  • Class Antineoplastics; Antirheumatics; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; P53 gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Rheumatoid arthritis
  • Discontinued Multiple sclerosis

Most Recent Events

  • 13 Nov 2017 Singapore’s Health Sciences Authority approves IND application for initiation of a phase II trial in Acute myeloid leukaemia
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In the elderly, In volunteers, In adults) in Singapore (PO)
  • 16 Aug 2017 ASLAN Pharmaceuticals enters in to a research collaboration with Academia Sinica for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top